Errodable, Resorbable, Or Dissolving Patents (Class 424/426)
-
Patent number: 8883768Abstract: Effective treatments for protecting against undesirable macrophage activity are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce or prevent macrophage activity. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to prevent transplant rejection for at least thirty days. In some embodiments, the relief can be for at least sixty days, or up to ninety days.Type: GrantFiled: February 26, 2009Date of Patent: November 11, 2014Assignee: Warsaw Orthopedic, Inc.Inventor: Vanja Margareta King
-
Patent number: 8883188Abstract: The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or bio medical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and bioresorption properties). The supramolecular bioresorbable or biomedical material is especially suitable for biomedical applications such as controlled release of drugs, materials for tissue-engineering, materials for the manufacture of a prosthesis or an implant, medical imaging technologies.Type: GrantFiled: May 3, 2006Date of Patent: November 11, 2014Assignee: SupraPolix B.V.Inventors: Patricia Yvonne Wilhelmina Dankers, Gaby Maria Leonarda Hoorne-Van Gemert, Henricus Marie Janssen, Egbert Willem Meijer, Anton Willem Bosman
-
Patent number: 8882850Abstract: A collagenous biomaterial medical device comprising a molded sponge material formed from comminuted submucosa fragments that have not been cross-linked with a cross-linking agent, wherein said submucosa has at least one biotropic agent, and wherein said biotropic agent is a growth factor is disclosed.Type: GrantFiled: October 31, 2007Date of Patent: November 11, 2014Assignee: Cook Biotech IncorporatedInventors: Michael C. Hiles, Umesh H. Patel
-
Patent number: 8877231Abstract: Compositions and methods are directed to antimicrobial compositions and articles that release .NO from the composition and/or article in an amount effective to prevent gingival and other oral mucosal diseases.Type: GrantFiled: June 24, 2011Date of Patent: November 4, 2014Inventor: Gerald Rosen
-
Patent number: 8877226Abstract: Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: GrantFiled: May 30, 2013Date of Patent: November 4, 2014Assignees: Medtronic, Inc., Warsaw Orthopedic, Inc.Inventors: John M. Zanella, Vanja M. King, Christopher M. Hobot, Stephen M. Cox, William F. McKay, Kathy L. Remsen
-
Patent number: 8877225Abstract: The present invention provides a constant release copolymer composition adapted for use in a controlled release formulation for a bioactive agent, such as a formulation adapted for implantation within a patient's body tissues as a depot to release the agent over a period of time, wherein the copolymer provides a substantially constant rate of release of the bioactive agent over the time period for which the depot persists in the body tissues. The copolymer includes a PLG copolymer and a PLG oligomer of about 5-10 kDa average molecular weight, which can lack free carboxylic acid groups. When the PLG copolymer is a low burst copolymer, the constant release copolymer composition is a low burst, constant release copolymer composition adapted for implantation in the body tissues of a mammal, wherein a substantially constant rate of release of the bioactive agent is achieved.Type: GrantFiled: June 3, 2009Date of Patent: November 4, 2014Assignee: Tolmar Therapeutics, Inc.Inventors: Richard L. Norton, Eric Dadey
-
Patent number: 8877215Abstract: Compositions and methods for modifying one or more biologic targets are provided. Suitable targets include cells, DNA, proteins, enzymes, and/or a subject in need thereof. The compositions may exist as a monomer or multimer and are active in a biologic environment with enhanced activity in hypoxic environments and, thus, exhibit improved specificity for hypoxic biologic targets (e.g., tumorigenic cells and those undergoing uncontrolled cell growth). A composition typically comprises a complex with an overall charge of 2+ or greater having at least one ruthenium atom attached to a redox active ligand. The redox active ligand helps maintain separation of more than one ruthenium atom. Suitable compositions may further include a terminal ligand comprising a heterocyclic aromatic compound. When provided to a biologic target, the composition modifies the biologic target and no additional compounds need be provided. Suitable compositions are typically catalytic and regenerative in the presence of a reducing agent.Type: GrantFiled: August 1, 2012Date of Patent: November 4, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Frederick M. MacDonnell, Thamara K. Janaratne, Sanjay Awashti
-
Patent number: 8877221Abstract: Osteoconductive matrices and methods are provided that have one or more statins disposed in calcium phosphate particles. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustained release of the statin and facilitate bone formation and repair of the fracture site.Type: GrantFiled: October 27, 2010Date of Patent: November 4, 2014Assignee: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20140322293Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.Type: ApplicationFiled: April 29, 2014Publication date: October 30, 2014Applicant: Hallux, Inc.Inventors: Frank Kochinke, Corinne Bright
-
Publication number: 20140322294Abstract: Biodegradable coatings for implantable medical devices are disclosed.Type: ApplicationFiled: July 3, 2014Publication date: October 30, 2014Inventor: Stephen Dirk Pacetti
-
Patent number: 8871243Abstract: A water soluble film that is disintegrable in the oral cavity to deliver an active agent is provided. The disintegrable film includes at least one water soluble polymer and an active agent. Also provided are methods for preparing the disintegrable oral film and for using the disintegrable film to administer an effective dosage of an active agent into the oral cavity for absorption through the oral mucosa. According to certain embodiments, the disintegrable film includes at least one water soluble polymer and a nicotine active.Type: GrantFiled: December 19, 2011Date of Patent: October 28, 2014Assignee: Novartis AGInventors: Christopher Edward Fankhauser, Greg Slominski, Stephan Meyer
-
Patent number: 8870954Abstract: The invention provides compositions and methods for treatment of tendon and ligament injuries and/or repair of damaged tendons and ligament. The invention provides compositions comprising a biocompatible matrix and platelet-derived growth factor (PDGF).Type: GrantFiled: September 9, 2009Date of Patent: October 28, 2014Assignee: BioMimetic Therapeutics, LLCInventors: Samuel E. Lynch, Leslie A. Wisner-Lynch, Hans K. Kestler, Yanchun Liu
-
Patent number: 8870945Abstract: A medical device has a structure made of a first biodegradable and/or bioabsorbable material and a second biodegradable and/or bioabsorbable material encapsulating a degradation additive incorporated into the first biodegradable and/or bioabsorbable material. The second biodegradable and/or bioabsorbable material has a degradation rate that is faster than the degradation rate of the first biodegradable and/or bioabsorbable material such that the structure experiences a period of accelerated degradation upon release of the degradation additive following sufficient degradation of the second biodegradable and/or bioabsorbable material.Type: GrantFiled: January 28, 2013Date of Patent: October 28, 2014Inventors: Vipul Dave, George Landau
-
Patent number: 8871241Abstract: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.Type: GrantFiled: November 13, 2003Date of Patent: October 28, 2014Assignee: pSivida US, Inc.Inventors: Kang-Jye Chou, Hong Guo, Paul Ashton, Robert W. Shimizu, David A. Watson
-
Patent number: 8871242Abstract: A blood anticoagulant material is provided which has high expandability, reduced influence on living bodies, and can efficiently prevent blood coagulation. A multiblock copolymer having at least a structural unit represented by Formula (1), a structural unit represented by Formula (2), and a structural unit represented by Formula (3) is used: wherein, R1, R2, and R3 in Formulas (1) to (3) each independently represent a divalent organic group, and m and n each independently represent an integer of 2 to 5000.Type: GrantFiled: November 16, 2007Date of Patent: October 28, 2014Assignee: National Cerebral and Cardiovascular CenterInventors: Tetsuji Yamaoka, Satoshi Kato, Atsushi Kasai, Sachiro Kakinoki
-
Patent number: 8871235Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.Type: GrantFiled: October 24, 2012Date of Patent: October 28, 2014Assignee: Synergy Biomedical LLCInventor: Mark D. Borden
-
Publication number: 20140314824Abstract: A porous artificial transplant material to replace autogenous bone with excellent biocompatibility, cytocompatibility and biodegradability is provided. More specifically, a porous scaffold for tissue engineering including chitosan/hydroxyapatite-amylopectin (Chitosan/HAp-AP) and a preparation method thereof are provided. The porous scaffold for tissue engineering has cross linkage among chitosan, hydroxyapatite and amylopectin, which provides advantageous effect including superior cell proliferation and transmission, and excellent thermal stability and mechanical strength. Further, considering excellent biocompatibility and biodegradability which do not harm human body, the porous scaffold can be widely used as an artificial transplant material to replace autogenous bone in biomedical field.Type: ApplicationFiled: August 30, 2012Publication date: October 23, 2014Inventors: Se-Kwon Kim, Venkatesan Jayachandran
-
Publication number: 20140314825Abstract: A porous, resorbable and flexible dental surgical membrane (16) is made from chitosan having a molecular weight of at least 400,000 daltons and has a thickness of from about 100 microns to about 0.5 mm. The membrane is easily insertable over a bone graft material site to confine the bone graft material (14) while allowing access to it of blood and oxygen. The high molecular weight of the chitosan may be chosen so that the membrane will not dissolve or resorb in a human mouth for a protracted period, e.g., from about 12 to about 16 weeks. The membrane is made by dissolving medical grade chitosan in aqueous acetic acid, dispersing fine silica particles into the solution to form a slurry, depositing a film of the slurry on a support surface, evaporating liquid from the slurry sufficiently to form a coherent chitosan membrane having silica particles dispersed therein, and then dissolving the silica particles with a sodium hydroxide solution followed by a water wash to form the porous chitosan membrane.Type: ApplicationFiled: November 20, 2012Publication date: October 23, 2014Inventors: Joseph F. Bristow, Bruno R. Stockinger
-
Patent number: 8858978Abstract: A method of curing and corresponding resulting non-polymeric cross-linked gel are provided. The cross-linked gel can be combined with a medical device structure. The cross-linked gel can provide anti-adhesion characteristics, in addition to improved healing and anti-inflammatory response. The cross-linked gel is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil, that is at least partially cured forming a cross-linked gel derived from at least one fatty acid compound. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent. The curing method can vary the application of heat in both temperature and duration to achieve a desired amount of cross-linking forming the gel.Type: GrantFiled: September 28, 2005Date of Patent: October 14, 2014Assignee: Atrium Medical CorporationInventors: Roger Labrecque, Philip McNamara, Joseph Ferraro, Lisa Rogers, Paul Martakos, Theodore Karwoski, Steve A. Herweck, Keith M. Faucher, Thomas M. Swanick
-
Patent number: 8858982Abstract: This invention is a prosthetic device generally placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material. Methods of perivascular antiproliferative drug administration also are disclosed.Type: GrantFiled: October 31, 2007Date of Patent: October 14, 2014Assignee: Vascular Therapies, LLCInventors: Sriram S. Iyer, Nicholas N. Kipshidze, Victor V. Nikolaychik
-
Patent number: 8858983Abstract: An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic acid, a glutathione peroxidase in combination with glutathione, or a superoxide dismutase in combination with a metal such as Ni, Cu, Mn, or Fe. In some examples, the antimicrobial accessory may include at least three polymer layers. For example, the antimicrobial accessory may include a first layer comprising a biodegradable polymer and an antimicrobial. The antimicrobial accessory may further include a sacrificial diffusion layer formed on a surface of the first layer. The sacrificial diffusion layer may include a biodegradable polymer, which may be the same biodegradable polymer as in the first layer or may be a different biodegradable polymer.Type: GrantFiled: March 16, 2010Date of Patent: October 14, 2014Assignee: Medtronic, Inc.Inventor: Robert E. Burgmeier
-
Patent number: 8858981Abstract: A bone healing combination material includes a matrix carrying cultivated bone-forming cells which may be osteocytes, osteoblasts, stromal stem cells or stem cells committed to differentiation into bone-forming osteoblasts. The matrix is a purified collagen matrix material derived from natural collagen-containing animal tissue, a collagen-free porous bone mineral matrix material derived from natural bone having a crystal structure substantially that of natural bone and being substantially free from endogenous organic material, or a combination of purified collagen matrix material and porous bone mineral matrix material.Type: GrantFiled: December 27, 2005Date of Patent: October 14, 2014Assignee: Ed. Geistlich Soehne Fuer Chemistrie IndustrieInventor: Peter Geistlich
-
Patent number: 8852625Abstract: A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.Type: GrantFiled: April 26, 2007Date of Patent: October 7, 2014Assignee: Micell Technologies, Inc.Inventors: James DeYoung, Doug Taylor, Jim McClain, Clint Smoke, Mike Cole
-
Publication number: 20140294913Abstract: This invention is related to bone fillers, hard tissue supporting films and three dimensional scaffolds that contains composite particle of inorganic compound/water soluble polymer (such as ?-TCP/Gelatin), that can lead to bone regeneration and release an antibacterial or bioactive agent at the defect area. The bone regenerative hard tissue supporting films and scaffolds were obtained by addition of antibacterial or bioactive agent loaded composite particles into biodegrable polymer (such as PCL) matrix.Type: ApplicationFiled: March 28, 2013Publication date: October 2, 2014Inventors: Nesrin Hasirci, Eda Ayse Aksoy, Umran Aydemir Sezer
-
Patent number: 8846068Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof, wherein the drug depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at a site beneath the skin and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days.Type: GrantFiled: April 8, 2009Date of Patent: September 30, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Amira Wohabrebbi, William F. McKay, Vanja Margareta King, Danielle L. Biggs, Katara Shaw, Christopher M. Hobot, Phillip Edward McDonald
-
Patent number: 8846070Abstract: A medical article is disclosed, comprising a biologically degradable AB block copolymer and a biologically degradable polymer that is capable, at equilibrium and at room temperature, of absorbing less than about 5 mass % water.Type: GrantFiled: July 29, 2008Date of Patent: September 30, 2014Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Yiwen Tang, Syed F. A. Hossainy, Andrew C. Tung, Stephen D. Pacetti
-
Patent number: 8846845Abstract: Absorbable polyurethanes, polyamides and polyester urethanes prepared from at least one compound selected from: or the corresponding diamines or diisocyanates thereof, wherein each X independently represents —CH2COO—, —CH(CH3)COO—, —CH2CH2OCH2COO—, —CH2CH2CH2CH2CH2COO—, —(CH2)yCOO— where y is 2 to 4 or 6 to 24, or —(CH2CH2O)z?CH2COO— where z? is 2 to 24; each Y represents —COCH2O—, —COCH(CH3)O—, —COCH2OCH2CH2O—, —COCH2CH2CH2CH2CH2O—, —CO(CH2)mO— where m is 2 to 4 or 6 to 24, or —COCH2O(CH2CH2O)n— where n is 2 to 24; R? is hydrogen, benzyl or straight-chained or branched alkyl; p is 1 to 4; and Rn represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid and —NO2, which is attached directly to an aromatic ring or attached through an aliphatic chain. Absorbable polymers prepared from these compounds are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention and other implantable medical devices.Type: GrantFiled: February 22, 2012Date of Patent: September 30, 2014Assignee: Bezwada Biomedical, LLCInventor: Rao S. Bezwada
-
Patent number: 8846072Abstract: The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided.Type: GrantFiled: March 7, 2013Date of Patent: September 30, 2014Assignee: Durect CorporationInventor: A. Neil Verity
-
Patent number: 8846836Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.Type: GrantFiled: September 28, 2012Date of Patent: September 30, 2014Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Thierry Glauser, Syed Faiyaz Ahmed Hossainy, Connie Kwok, Stephen Dirk Pacetti, Eugene Michal
-
Patent number: 8846071Abstract: A stent having a stent body made from a crosslinked bioabsorbable polymer is disclosed. A method of making the stent including exposing a tube formed from a bioabsorbable polymer to radiation to crosslink the bioabsorbable polymer and forming a stent body from the exposed tube is disclosed. The tube can include a crosslinking agent which induces crosslinking upon radiation exposure. Additionally or alternatively, the bioabsorbable polymer can be a copolymer that crosslinks upon exposure to radiation in the absence of a crosslinking agent.Type: GrantFiled: February 17, 2012Date of Patent: September 30, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventor: Lothar W. Kleiner
-
Publication number: 20140287006Abstract: The present invention relates to degradation-stabilised, biocompatible collagen matrices which are distinguished in particular by the fact that they contain soluble collagen and peptide constituents, to processes for the preparation of such collagen matrices, which processes include in particular chemical crosslinking with an epoxy-functional crosslinking agent, and to the use of the collagen matrices according to the invention as a cosmetic or pharmaceutical agent, in particular for topical use, and as a wound treatment agent, as an implant or as a haemostatic agent in humans or animals, and as a scaffold for cell population in the biotechnology, basic research and tissue engineering field.Type: ApplicationFiled: March 28, 2014Publication date: September 25, 2014Inventors: Ralf Malessa, Anja Kassner
-
Patent number: 8840917Abstract: An implantable graft, which may be inserted into a fistula tract to occlude the primary opening of the fistula, is provided. To prevent unintentional displacement of the graft or extrusion of the graft from the fistula of a patient, the graft may be provided with a cap that extends laterally from at least one end of the body of the graft, where the cap may be integral with the body of the graft, attachable to at least one end of the body of the graft, and/or moveable along the body of the graft. The graft may also have a tail that extends from one end of the body of the graft to assist in placement of the graft in a fistula tract. The graft may be an integral unit made of a single material, such as a heterograft material, or may include distinct components made of the same or different materials. Methods for closing a fistula tract are also provided.Type: GrantFiled: July 15, 2013Date of Patent: September 23, 2014Assignees: Cook Medical Technologies LLC, Cook Biotech IncorporatedInventors: David N. Armstrong, Brian L. Bates, Mark W. Bleyer, F. Joseph Obermiller, Umesh H. Patel
-
Patent number: 8840915Abstract: The present invention provides methods of forming a solid, biodegradable implant in-situ in a body by administering a liquid pharmaceutical composition comprising an effective amount of a biocompatible, water-insoluble, biodegradable polymer and an effective amount of a therapeutic peptide covalently modified with one or more lipophilic or amphiphilic moieties, which are dissolved or dispersed in a biocompatible, water-soluble organic solvent. This invention also provides related compositions and methods.Type: GrantFiled: May 25, 2012Date of Patent: September 23, 2014Assignee: Foresec Pharmaceuticals, LLCInventors: Yuhua Li, Benjamin Chien
-
Patent number: 8841408Abstract: Biocompatible macromonomers, hydrogels, methods of synthesis and methods of use thereof are provided. The biocompatible hydrogels of the present invention are prepared using native chemical ligation (NCL), in which a thioester readily reacts with a N-terminal thiol (cysteine) through transesterification and rearrangement to form an amide bond through a five-member ring intermediate.Type: GrantFiled: April 21, 2008Date of Patent: September 23, 2014Assignee: Northwestern UniversityInventors: Phillip B Messersmith, Bi-Huang Hu, Jing Su
-
Patent number: 8840916Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.Type: GrantFiled: May 22, 2013Date of Patent: September 23, 2014Assignee: Tolmar Therapeutics, Inc.Inventor: Richard L. Dunn
-
Publication number: 20140271471Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminoglycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
-
Publication number: 20140271779Abstract: Synthetic, bioactive ultra-porous bone graft materials having an engineered porosity, and implants formed from such materials are provided. In particular, these implants comprise bioactive glass and incorporate allograft material for osteoinduction. The implants are suitable for bone tissue regeneration and/or repair.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: PROSIDYAN, INC.Inventors: Charanpreet S. BAGGA, Steve B. JUNG, Hyun W. BAE
-
Patent number: 8834914Abstract: The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions.Type: GrantFiled: December 22, 2010Date of Patent: September 16, 2014Assignee: Zimmer, Inc.Inventors: Neil Kizer, Robert Spiro, Jian Yao, Cheryl Renee Blanchard
-
Patent number: 8834901Abstract: The present invention discloses polymeric materials that incorporate a modified quinone moiety, either to cross-link the polymer or as a monomeric unit of the polymer. These polymeric materials can be efficiently degraded through electrochemical reduction of the quinone leading to rapid hydrolysis of the pendant chemical groups and degradation of the polymer. Quinone-containing compositions and methods of producing electrochemically degradable polymers are disclosed. The methods and compositions of the present invention can be used in a wide variety of applications, including, but not limited to, drug delivery, tissue regeneration, biomedical implants, and electronic systems.Type: GrantFiled: October 14, 2005Date of Patent: September 16, 2014Assignee: Trustees of Tufts CollegeInventors: Marc d'Alarcao, Pericles Calias
-
Patent number: 8834913Abstract: A medical implant device having a substrate with an oxidized surface and a silane derivative coating covalently bonded to the oxidized surface. A bioactive agent is covalently bonded to the silane derivative coating. An implantable stent device including a stent core having an oxidized surface with a layer of silane derivative covalently bonded thereto. A spacer layer comprising polyethylene glycol (PEG) is covalently bonded to the layer of silane derivative and a protein is covalently bonded to the PEG. A method of making a medical implant device including providing a substrate having a surface, oxidizing the surface and reacting with derivitized silane to form a silane coating covalently bonded to the surface. A bioactive agent is then covalently bonded to the silane coating. In particular instances, an additional coating of bio-absorbable polymer and/or pharmaceutical agent is deposited over the bioactive agent.Type: GrantFiled: December 28, 2009Date of Patent: September 16, 2014Assignee: Battelle Memorial InstituteInventors: Wendy J. Shaw, Clement R. Yonker, John L. Fulton, Barbara J. Tarasevich, James B. McClain, Doug Taylor
-
Patent number: 8834915Abstract: Methods for producing drug-containing bioabsorbable fibers. Also disclosed are methods for treating diseases using a bioabsorbable drug delivery device.Type: GrantFiled: March 30, 2012Date of Patent: September 16, 2014Assignee: Manli International Ltd.Inventors: Shih-Horng Su, Ting-Bin Yu, Minh Nguyen
-
Patent number: 8828419Abstract: A medical device has a structure made of one biodegradable and/or bioabsorbable material. A degradation additive is encapsulated by another biodegradable and/or bioabsorbable material forming a nanoparticle or microparticle. The nanoparticle or microparticle is together with the one biodegradable and/or bioabsorbable material of the structure. The other biodegradable and/or bioabsorbable material of the nanoparticle or microparticle has a degradation rate that is faster than a degradation rate of the one biodegradable and/or bioabsorbable material. The structure experiences a period of accelerated degradation upon release of the degradation additive from the nanoparticle or microparticle.Type: GrantFiled: October 6, 2006Date of Patent: September 9, 2014Inventors: Vipul Davé, George Landau
-
Publication number: 20140248329Abstract: Surgical implants of the present disclosed include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate.Type: ApplicationFiled: May 12, 2014Publication date: September 4, 2014Applicant: Covidien LPInventors: Joshua Stopek, Amin Elachchabi, Daniel Broom, Garrett Ebersole
-
Patent number: 8821913Abstract: The present invention relates to a controlled release system, in particular to a controlled release system containing temozolomide.Type: GrantFiled: September 29, 2003Date of Patent: September 2, 2014Assignee: Tasly Holding Group Co., Ltd.Inventors: Yongfeng Wang, Dan Fei
-
Patent number: 8821849Abstract: One aspect of the present invention relates to a method of occluding a vascular site in a mammal, comprising the step of introducing into the vasculature of a mammal at or proximal to a surgical site, a composition comprising at least one optionally purified inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily occluding a vascular site of said mammal, wherein said temporarily occluded vasculature site is kept in a substantially cylindrical shape.Type: GrantFiled: March 26, 2010Date of Patent: September 2, 2014Assignee: Genzyme CorporationInventor: Alexander Schwarz
-
Patent number: 8815274Abstract: The present invention generally encompasses a medical article, such as a medical device or coating comprising an agent or combination of agents, wherein the agent is distributed throughout a polymeric matrix. The polymeric matrix comprises an agent and a poly(ester amide) having a design that was preselected to provide a predetermined release rate of the combination of agents from the medical article.Type: GrantFiled: June 4, 2009Date of Patent: August 26, 2014Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Jessica R. DesNoyer, Stephen D. Pacetti, Lothar W. Kleiner, Syed F. A. Hossainy, Yung-Ming Chen, Gordon Stewart, Gina Zhang
-
Patent number: 8808726Abstract: Bioerodible endoprostheses and methods of making the endoprostheses are disclosed. In some embodiments, an endoprosthesis includes a member including a bioerodible material, and an antioxidant carried by the member. Examples of antioxidants include phenols.Type: GrantFiled: September 14, 2007Date of Patent: August 19, 2014Assignee: Boston Scientific SciMed. Inc.Inventors: Liliana Atanasoska, Jan Weber, Robert W. Warner, Amy Grovender
-
Publication number: 20140227337Abstract: The present invention relates to devices and related methods for treating fistulas such as anal or recto-vaginal fistulas, in particular by the use of a seton to secure a tissue growth promoter such as a growth factor and/or fibrin. The various devices are particularly suitable for positioning tissue growth promoters securely within a fistula. Thus, one device comprises a seton and a tissue growth promoter. Further related aspects of the invention included devices comprising an enclosure provided in between portions of a seton, devices comprising a seton and a plurality of holes for enabling the device to be sutured to tissue, devices comprising a probe and a seton that are releasably connectable end-to-end, devices comprising an attachment device to secure the ends of a seton, and devices comprising a fistula plug adapted to be secured to a section.Type: ApplicationFiled: September 26, 2011Publication date: August 14, 2014Applicant: KEIGHLEYCOLO LTDInventor: Michael Robert Burch Keighley
-
Publication number: 20140227338Abstract: Porous polymers having a plurality of openings or chambers that are highly convoluted, with each chamber being defined by multiple, thin, flat partitions are produced by a new gel enhanced phase separation technique. In a preferred embodiment, a second liquid is added to a polymer solution, the second liquid causing the solution to increase in viscosity. With sufficient polymer and second liquid present, the increase in viscosity can be up to that of a gel. The gel can then be shaped as needed. Subsequent solvent extraction leaves the porous polymeric body of defined shape. The porous polymers have utility as medical prostheses, the porosity permitting ingrowth of neighboring tissue. A second material may be incorporated into the chambers, thereby creating a microstructure filling the voids of the macrostructure.Type: ApplicationFiled: April 15, 2014Publication date: August 14, 2014Applicant: Kensey Nash CorporationInventor: Timothy A. Ringeisen
-
Patent number: 8802124Abstract: The present invention provides a dissolvable medical sealing device (3, 4; 6, 7; 9) for closing a wound in vessel. A sealing device (3, 4, 6, 7, 9) according to the invention is made of a material that dissolves by means of physical processes, rather than by means of chemical or biological processes. Such a sealing device (3, 4; 6, 7; 9) can be made of polyethylene glycol, polypropylene glycol, copolymers containing ethylene glycol and propylene glycol, polyvinyl alcohol or polyvinyl pyrolidone, or any combinations thereof.Type: GrantFiled: April 24, 2003Date of Patent: August 12, 2014Assignee: Radi Medical Systems ABInventors: Lars Tenerz, Dan Åkerfeldt, Torbjörn Mathisen